Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL.
暂无分享,去创建一个
A. Rosenwald | S. Barrans | E. Leich | A. Banham | P. Brown | K. Pulford | C. Burek | J. Fenton | A. Jack | S. Ashe
[1] R. Kagaya,et al. Characterization of human FOXP1 isoform 2, using monoclonal antibody 4E3‐G11, and intron retention as a tissue‐specific mechanism generating a novel FOXP1 isoform , 2008, Histopathology.
[2] Ncbi. National Center for Biotechnology Information , 2008 .
[3] A. Ng,et al. Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.
[4] S. Barrans,et al. Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement. , 2007, Haematologica.
[5] C. Meijer,et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] L. Staudt,et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma , 2007, The Journal of experimental medicine.
[7] H. Noels,et al. The pathogenesis of MALT lymphomas: where do we stand? , 2007, Leukemia.
[8] J. Thierry-Mieg,et al. AceView: a comprehensive cDNA-supported gene and transcripts annotation , 2006, Genome Biology.
[9] J. Nardone,et al. Foxp1 is an essential transcriptional regulator of B cell development , 2006, Nature Immunology.
[10] A. Rosenwald,et al. Genetic rearrangement of FOXP1 is predominantly detected in a subset of diffuse large B-cell lymphomas with extranodal presentation , 2006, Leukemia.
[11] P. de Paepe,et al. Forkhead box protein P1 expression in mucosa-associated lymphoid tissue lymphomas predicts poor prognosis and transformation to diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] L. Pham,et al. Constitutive NF-κB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas , 2006 .
[13] S. Barrans,et al. t(3;14)(p14;q32) Results in aberrant expression of FOXP1 in a case of diffuse large B‐cell lymphoma , 2006, Genes, chromosomes & cancer.
[14] L. Pham,et al. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. , 2006, Blood.
[15] R. Kodet,et al. Identification of potential human oncogenes by mapping the common viral integration sites in avian nephroblastoma. , 2006, Cancer research.
[16] C. Massone,et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. , 2005, Blood.
[17] P. Marynen,et al. FOXP1, a gene highly expressed in a subset of diffuse large B-cell lymphoma, is recurrently targeted by genomic aberrations , 2005, Leukemia.
[18] E. Bettelli,et al. Foxp3 interacts with nuclear factor of activated T cells and NF-kappa B to repress cytokine gene expression and effector functions of T helper cells. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] A. Chott,et al. T(3;14)(p14.1;q32) involving IGH and FOXP1 is a novel recurrent chromosomal aberration in MALT lymphoma , 2005, Leukemia.
[20] R. Gascoyne,et al. Expression of the FOXP1 transcription factor is strongly associated with inferior survival in patients with diffuse large B-cell lymphoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[21] L. Staudt,et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling , 2005 .
[22] L. Staudt,et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] A. Banham,et al. The FOXP1 Transcription Factor is Expressed in the Majority of Follicular Lymphomas but is Rarely Expressed in Classical and Lymphocyte Predominant Hodgkin’s Lymphoma , 2005, Journal of Molecular Histology.
[24] S. Barrans,et al. Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. , 2004, Blood.
[25] Bin Wang,et al. Foxp1 regulates cardiac outflow tract, endocardial cushion morphogenesis and myocyte proliferation and maturation , 2004, Development.
[26] S. Fox,et al. Expression of the Forkhead Transcription Factor FOXP1 Is Associated with Estrogen Receptor α and Improved Survival in Primary Human Breast Carcinomas , 2004, Clinical Cancer Research.
[27] L. Staudt,et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.
[28] Philip Tucker,et al. Multiple Domains Define the Expression and Regulatory Properties of Foxp1 Forkhead Transcriptional Repressors* , 2003, Journal of Biological Chemistry.
[29] L. Staudt,et al. Decision making in the immune system: Lymphoid Malignancies: the dark side of B-cell differentiation , 2002, Nature Reviews Immunology.
[30] Meland,et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.
[31] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[32] Ulrich Siebenlist,et al. Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells , 2001, The Journal of experimental medicine.
[33] C Fidler,et al. The FOXP1 winged helix transcription factor is a novel candidate tumor suppressor gene on chromosome 3p. , 2001, Cancer research.
[34] S. Gerondakis,et al. Rel/NF‐κB transcription factors: key mediators of B‐cell activation , 2000 .
[35] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[36] L. Staudt,et al. BCL-6 expression during B-cell activation. , 1996, Blood.